Details of the Drug

General Information of Drug (ID: )

Indication

Disease Entry	ICD 11	Status	REF
Metastatic colorectal cancer	2B91	Phase 3	[1]
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Hepatocellular carcinoma	2C12.02	Phase 2	[2]
Hypopharyngeal squamous cell carcinoma	2B6D.0	Phase 1/2	[3]

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[4]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[4]

Molecular Expression Atlas of This Drug

• The Studied Disease: Metastatic colorectal cancer
• ICD Disease Classification: 2B91

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	3.61E-01	0.15	0.47

References

• [1] ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
• [2] ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• [4] Clinical pipeline report, company report or official report of Roche (2009).